Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of bortezomib under standard rituximab therapy in relapsed or refractory follicular lymphoma
2005-003949-14Phase 2Completed
- Sponsor
- Janssen-Cilag
- Start
- Oct 2005
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in follicular lymphoma (FL), sponsored by Janssen-Cilag. Primary endpoint: Time to progression or relapse. Started Oct 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2005-003949-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003949-14.